Ignite Creation Date:
2025-12-24 @ 9:56 PM
Ignite Modification Date:
2025-12-25 @ 7:34 PM
Study NCT ID:
NCT06073132
Status:
RECRUITING
Last Update Posted:
2025-11-19
First Post:
2023-09-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016110', 'term': 'Epidermolysis Bullosa Simplex'}], 'ancestors': [{'id': 'D004820', 'term': 'Epidermolysis Bullosa'}, {'id': 'D012868', 'term': 'Skin Abnormalities'}, {'id': 'D000013', 'term': 'Congenital Abnormalities'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D012873', 'term': 'Skin Diseases, Genetic'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D012872', 'term': 'Skin Diseases, Vesiculobullous'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C025292', 'term': 'diacerein'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 80}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-04-04', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2027-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-17', 'studyFirstSubmitDate': '2023-09-12', 'studyFirstSubmitQcDate': '2023-10-03', 'lastUpdatePostDateStruct': {'date': '2025-11-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2023-10-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients achieving treatment success on the IGA of the Treatment Area, in which treatment success is defined as a score of 0 or 1 with at least a 2-point reduction', 'timeFrame': 'from Baseline A (Visit 2/Day 1) to Week 8 (Visit 5/EOT)', 'description': "The static IGA is the investigator's visual clinical assessment of the average overall intensity of lesions in the designated Treatment Area at a particular time point. EBS-IGA is a 5-point scale is a 5-point scale (clear=0; almost clear=1; mild=2; moderate=3; severe=4)"}], 'secondaryOutcomes': [{'measure': 'Change in % BSA of EBS lesions in the Treatment Area', 'timeFrame': 'from Baseline A (Visit 2/Day 1) to Week 8 (Visit 5/EOT)', 'description': 'The Body Surface Area (BSA) of the Assessment Area will be collected for all lesions included within the Treatment Area using the palmar method'}, {'measure': 'Change in pain intensity score', 'timeFrame': 'Baseline A (Visit 2/Day 1) to Week 8 (Visit 5/EOT)', 'description': 'Wong-Baker FACES® Pain Rating Scale will be used for patients 3 years and older.'}, {'measure': 'Change in pruritus intensity score', 'timeFrame': 'from Baseline A (Visit 2/Day 1) to Week 8 (Visit 5/EOT)', 'description': 'ItchyQuant will be used for patients aged 6 years and older, including adult patients'}, {'measure': 'Change in EBDASI score (skin activity)', 'timeFrame': 'from Baseline A (Visit 2/Day 1) to Week 8 (Visit 5/EOT).', 'description': 'The EBDASI is a valid and reliable EB-specific outcome measurement tool to assess the overall extent of disease activity and damage in patients with various subtypes of EB, including EBS. Section I (skin), the severity of disease, including erosion/blisters/crusting etc., will be measured at 12 different skin sites.'}, {'measure': 'Change in the QOLEB score', 'timeFrame': 'from Baseline A (Visit 2/Day 1) to Week 8 (Visit 5/EOT)', 'description': 'The Life Epidermolysis Bullosa (QOLEB) questionnaire is a valid and reliable, EB-specific QOL measurement tool, for the quantification of QOL in patients with various subtypes of EB, including EBS. It consists of 17 questions with four response choices from "not at all" to "constant"'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Epidermolysis Bullosa Simplex', 'EBS'], 'conditions': ['Generalized Epidermolysis Bullosa Simplex']}, 'descriptionModule': {'briefSummary': 'The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.', 'detailedDescription': 'Epidermolysis bullosa simplex (EBS) is a genetic skin disorder characterized by skin fragility and recurrent blister formation, primarily caused by mutations in keratins 5 and 14. EBS has 3 common subtypes based on clinical severity and manifestations: localized EBS, intermediate EBS and severe EBS. Severe EBS and intermediate EBS collectively are also known as generalized EBS due to widespread blistering.\n\nDisruption of the keratin 5/14 filament network in basal keratinocytes is a key factor in EBS pathogenesis, compromising skin integrity. The severity of EBS is linked to the extent of keratin mutations disrupting this network, particularly resulting in keratin aggregates in severe cases. Recent studies suggest that mutated keratin proteins can trigger inflammation, exacerbating EBS. Elevated proinflammatory cytokines, like IL-1β and IL-6, are observed in EBS patients, and IFN-γ may mediate inflammation, promoting keratin aggregations. As a result, targeting inflammation is considered a potential therapeutic approach in EBS.\n\nAC-203 (diacerein 1% ointment) is a topical formulation of diacerein, well-known for its ability to inhibit IL-1β and other proinflammatory cytokines. Moreover, diacerein and its active metabolite, rhein, have demonstrated ability in reducing keratin aggregates in keratinocytes derived from severe EBS. Taken together, with its anti-inflammatory property and ability to diminish keratin aggregation, AC-203 shows promise in reducing the clinical severity of EBS.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '6 Months', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Patient is at least 6 months old at Visit 2 (Day 1/Baseline A).\n2. Patients has been clinically diagnosed with severe EBS or intermediate EBS, confirmed by documented genetic diagnosis to have autosomal dominant mutations in KRT5 or KRT14 gene.\n3. Patient with ≥ 3% BSA of EBS lesions excluding palms and soles at Visit 2 (Day 1/Baseline A).\n4. Patient's EBS lesions within the Treatment Area have an IGA score of ≥3 at Visit 2 (Day 1/Baseline A).\n5. Patient/caregiver agrees to follow study medication application instructions.\n6. Patient (and caregiver/legal guardian) agrees to report use of all prescription and over-the-counter medications, including topical therapies applied to the body, e.g., medical cleansers, bleach cleansers, bleach baths, topical antiseptics, topical disinfectants, etc. for the duration of the study.\n7. Patient (and caregiver/legal guardian) is willing and able to comply with all study visits and all the protocol requirements, including completing questionnaires.\n8. Patient (and caregiver/legal guardian) is able to provide written informed consent; assent based on age.\n9. Female patient of childbearing potential must have a negative pregnancy test prior to randomization.\n10. Female patient of childbearing potential is willing to practice highly effective contraception (i.e., pregnancy prevention method with a failure rate of \\< 1% per year) from Screening throughout the end of the study.\n\nExclusion Criteria:\n\n1. Patient has a clinically significant skin disease other than EBS (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or a vascular disorder associated with cutaneous erosions/ulcerations, that may confound assessments of efficacy or safety.\n2. Patient has a clinically significant underlying medical condition, psychiatric condition (such as major depressive or psychotic disorder, severe intellectual disability, or alcohol or drug use disorder), or requires concomitant medication that based on the investigator's judgement may impair evaluation of the Treatment Area or exposes the patient to an unacceptable risk by study participation.\n3. Patient has used any diacerein-containing product within 6 months prior to Visit 2 (Day 1/Baseline A).\n4. Patient has had a cutaneous infection in the Treatment Area or use systemic antibiotics within 7 days prior to Visit 2 (Day 1/Baseline A).\n5. Patient has uncontrolled diabetes mellitus (HbA1c ≥ 6.5%), hepatic enzyme abnormalities (alanine aminotransferase or aspartate aminotransferase \\>2.5 the upper limit of normal (ULN), or total bilirubin \\>2.0x ULN), or renal abnormalities (estimated glomerular filtration rate \\[eGFR\\]\\< 30 ml/min/1.73 m2) during the Screening period.\n6. Patient has a current malignancy, or a history of treatment for a malignancy within 5 years (with the exception of treated non-melanoma cutaneous malignancy e.g., surgically resected with clear margins) prior to Visit 2 (Day 1/Baseline A).\n7. Patient is treated with protocol-excluded topical therapies other than steroids within 2 weeks prior to Visit 2 (Day 1/Baseline A) that might influence the assessment of the Treatment Area throughout the study period.\n8. Patient has been treated with topical steroids on the EBS lesions within 2 weeks or systemic steroids within 4 weeks. prior to Visit 2 (Day 1/Baseline A). (Note: inhaled and ophthalmic products containing steroids are allowed.)\n9. Patient has been treated with: (a) an approved biologic anti-inflammatory therapy (such as monoclonal antibodies that target to modulate the immune responses) and (b) other immunosuppressive/immunomodulatory therapies or chemotherapy within 8 weeks prior to Visit 2 (Day 1/Baseline A).\n10. Patient has been treated with any investigational drug or device within 30 days or 5 half-lives, whichever is longer, prior to Visit 2 (Day 1/Baseline A).\n11. Patient has a history of allergy or hypersensitivity to any component of study medications, including diacerein or rhein.\n12. Patient is pregnant or breastfeeding/lactating.\n13. Patient has a planned or anticipated major surgical procedure or other activity that would interfere with their ability to comply with protocol requirements."}, 'identificationModule': {'nctId': 'NCT06073132', 'acronym': 'EBShield', 'briefTitle': 'An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)', 'organization': {'class': 'INDUSTRY', 'fullName': 'TWi Biotechnology, Inc.'}, 'officialTitle': 'An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]', 'orgStudyIdInfo': {'id': 'AC-203-EBS-007'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part A AC-203', 'description': 'Double-blind, AC-203 Diacerein 1% ointment, QD', 'interventionNames': ['Drug: AC-203']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part A Vehicle ointment', 'description': 'Double-blind, Vehicle ointment, QD', 'interventionNames': ['Drug: Vehicle']}, {'type': 'EXPERIMENTAL', 'label': 'Part B AC-203', 'description': 'Open-label extension phase, AC-203 Diacerein 1% ointment, QD', 'interventionNames': ['Drug: AC-203']}], 'interventions': [{'name': 'AC-203', 'type': 'DRUG', 'description': 'The investigational product is formulated as 1% topical ointment', 'armGroupLabels': ['Part A AC-203', 'Part B AC-203']}, {'name': 'Vehicle', 'type': 'DRUG', 'description': 'Vehicle-only control study medication is the same formulation as investigational product without active ingredient', 'armGroupLabels': ['Part A Vehicle ointment']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92688', 'city': 'Rancho Santa Margarita', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Shireen Guide, MD', 'role': 'CONTACT'}], 'facility': 'Mission dermatology Center', 'geoPoint': {'lat': 33.64086, 'lon': -117.6031}}, {'zip': '94304', 'city': 'Stanford', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Joyce Teng, MD PhD', 'role': 'CONTACT'}], 'facility': 'Stanford University', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Anna Bruckner, MD', 'role': 'CONTACT'}], 'facility': "Children's Hospital Colorado", 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '33146', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mercedes Gonzalez, MD', 'role': 'CONTACT'}], 'facility': 'Pediatric Skin Research, LLC', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Amy S. Paller, MD', 'role': 'CONTACT'}], 'facility': "Northwestern University - Lurie Childrens's Hospital", 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '11790', 'city': 'Stony Brook', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jordan Slutsky, MD', 'role': 'CONTACT'}], 'facility': 'Stony Brook Dermatology', 'geoPoint': {'lat': 40.92565, 'lon': -73.14094}}, {'zip': '45229', 'city': 'Cincinnati', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Kalyani Marathe, MD, MPH', 'role': 'CONTACT'}], 'facility': 'Cincinnati Childrens Hospital', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '29425', 'city': 'Charleston', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Lara Wine Lee, MD PhD', 'role': 'CONTACT'}], 'facility': 'Medical University of South Carolina', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '78218', 'city': 'San Antonio', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jennifer Patterson', 'role': 'CONTACT', 'email': 'jpatterson@texasdls.com'}, {'name': 'John C. Browning, MD', 'role': 'CONTACT'}], 'facility': 'Texas Dermatology and Laser Specialists', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '3052', 'city': 'Melbourne', 'state': 'Victoria', 'status': 'NOT_YET_RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Laura Scardamaglia, MD', 'role': 'CONTACT'}], 'facility': 'Royal Melbourne Hospital', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'city': 'Kogarah', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Dedee Murrell, MD', 'role': 'CONTACT'}], 'facility': 'Premier Specialists', 'geoPoint': {'lat': -33.9681, 'lon': 151.13564}}, {'city': 'Randwick', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Artiene Tatian, MD', 'role': 'CONTACT'}], 'facility': "Sydney Children's Hospital", 'geoPoint': {'lat': -33.91439, 'lon': 151.24895}}, {'city': 'Salzburg', 'status': 'RECRUITING', 'country': 'Austria', 'contacts': [{'name': 'Martin Laimer, MD', 'role': 'CONTACT'}], 'facility': 'Universitaetsklinik fuer Dermatologie und Allergologie', 'geoPoint': {'lat': 47.79941, 'lon': 13.04399}}, {'city': 'Leuven', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Caroline Colmant, MD', 'role': 'CONTACT'}], 'facility': 'UZ Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Christine Bodemer, MD, PhD', 'role': 'CONTACT'}], 'facility': 'Hopital Necker-Enfants Malades', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '16121', 'city': 'Athens', 'status': 'NOT_YET_RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'Alexandros Stratigos, MD', 'role': 'CONTACT'}], 'facility': 'Andreas Syggros Hospital 1st University Clinic of Skin and Venereal Diseases of Athens', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'city': 'Thessaloniki', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'Dimitra Kyritsi, MD', 'role': 'CONTACT'}], 'facility': 'Hospital of Skin and Venereal Diseases of Thessaloniki', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'city': 'Chandigarh', 'status': 'RECRUITING', 'country': 'India', 'contacts': [{'name': 'Rahul Mahajan, MD', 'role': 'CONTACT'}], 'facility': 'Postgraduate Institute of Medical Education and Research (PGIMER)', 'geoPoint': {'lat': 30.73629, 'lon': 76.7884}}, {'city': 'Dublin', 'status': 'RECRUITING', 'country': 'Ireland', 'contacts': [{'name': 'Fiona Browne, MD', 'role': 'CONTACT'}], 'facility': "Children's Health Ireland", 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Mor Pavlosky, MD', 'role': 'CONTACT'}], 'facility': 'Tel Aviv Sourasky Medical Center', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'city': 'Bologna', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Iria Neri, MD', 'role': 'CONTACT'}], 'facility': "IRCCS, AOUBO, Policlinico Sant'Orsola", 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'city': 'Milan', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Sophie Guez, MD', 'role': 'CONTACT'}], 'facility': "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano", 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'city': 'Modena', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Cristina Magnoni, MD', 'role': 'CONTACT'}], 'facility': 'Università degli Studi di Modena e Reggio Emilia (UNIMORE)', 'geoPoint': {'lat': 44.64783, 'lon': 10.92539}}, {'city': 'Rome', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Biagio Didona, MD', 'role': 'CONTACT'}], 'facility': "Istituto Dermopatico dell'Immacolata (IDI) - Istituto di", 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'city': 'Rome', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Andrea Diociaiuti, MD', 'role': 'CONTACT'}], 'facility': 'UOS "Centro delle Dermatosi Croniche Complesse e Genodermatosi" UOC Dermatologia', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'city': 'Kuala Lumpur', 'status': 'RECRUITING', 'country': 'Malaysia', 'contacts': [{'name': 'Kin Fon Leong, MD', 'role': 'CONTACT'}], 'facility': 'Hospital Tunku Azizah (Hospital Wanita Dan Kanak-kanak Kuala Lumpur)', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'city': 'City of Muntinlupa', 'status': 'RECRUITING', 'country': 'Philippines', 'contacts': [{'name': 'Emerson Vista, MD', 'role': 'CONTACT'}], 'facility': 'Asian Hospital', 'geoPoint': {'lat': 14.39028, 'lon': 121.0475}}, {'city': 'Iloilo City', 'status': 'RECRUITING', 'country': 'Philippines', 'contacts': [{'name': 'Anjuli Jaen, MD', 'role': 'CONTACT'}], 'facility': 'Iloilo Doctors Hospital', 'geoPoint': {'lat': 10.69694, 'lon': 122.56444}}, {'city': 'Mandaluyong', 'status': 'RECRUITING', 'country': 'Philippines', 'contacts': [{'name': 'Mae Quizon, MD', 'role': 'CONTACT'}], 'facility': 'Health Cube Medical Clinics', 'geoPoint': {'lat': 14.5832, 'lon': 121.0409}}, {'city': 'Warsaw', 'status': 'RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Katarzyna Osipowicz, MD', 'role': 'CONTACT'}], 'facility': 'OT.CO Clinic Osipowicz & Turkowski', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Sang Eun Lee, MD', 'role': 'CONTACT'}], 'facility': 'Gangnam Severane Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Rocio Maseda Pedrero, MD', 'role': 'CONTACT'}], 'facility': 'Hospital Universitario La Paz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Tainan', 'status': 'RECRUITING', 'country': 'Taiwan', 'contacts': [{'name': 'Chao-Kai Hsu, MD PhD', 'role': 'CONTACT'}], 'facility': 'National Cheng Kung University Hospital', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'city': 'Abu Dhabi', 'status': 'RECRUITING', 'country': 'United Arab Emirates', 'contacts': [{'name': 'Shaden Mohammad Abdel Hadi, MD', 'role': 'CONTACT'}], 'facility': 'Sheikh Khalifa Medical City (SKMC)', 'geoPoint': {'lat': 24.45118, 'lon': 54.39696}}, {'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Anna Martinez, MD', 'role': 'CONTACT'}], 'facility': 'Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust - Somers Clinical Research Facility (CRF)', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Solihull', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Ajoy Bardhan, MD', 'role': 'CONTACT'}], 'facility': 'University Hospitals Birmingham NHS Foundation Trust (UHB)', 'geoPoint': {'lat': 52.41426, 'lon': -1.78094}}], 'centralContacts': [{'name': 'Sandy Lin, PhD', 'role': 'CONTACT', 'email': 'sandy.lin@twibiotech.com', 'phone': '+886-2-2657-1788'}, {'name': 'TWiB', 'role': 'CONTACT', 'email': 'twib-ebs@twibiotech.com', 'phone': '+886-2-2657-1788'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'TWi Biotechnology, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}